Massimo Breccia

Pubblicazioni

Titolo Pubblicato in Anno
First-hit SETBP1 mutations cause a myeloproliferative disorder with bone marrow fibrosis BLOOD 2024
Neutrophil to lymphocyte ratio in myelofibrosis patients treated with ruxolitinib may predict prognosis and rate of discontinuation EUROPEAN JOURNAL OF HAEMATOLOGY 2024
Ropeginterferon alfa-2b treatment in a young patient with multi-refractory polycythemia vera and double JAK2 gene mutation: a case report FRONTIERS IN ONCOLOGY 2024
Safety and Efficacy of TKIs in very Elderly Patients (≥75 Years) with Chronic Myeloid Leukemia JOURNAL OF CLINICAL MEDICINE 2024
How to improve treatment-free remission eligibility in chronic myeloid leukaemia? BRITISH JOURNAL OF HAEMATOLOGY 2024
e14a2 Transcript Favors Treatment-Free Remission in Chronic Myeloid Leukemia When Associated with Longer Treatment with Tyrosine Kinase Inhibitors and Sustained Deep Molecular Response JOURNAL OF CLINICAL MEDICINE 2024
Leucocytosis during induction therapy with all-trans-retinoic acid and arsenic trioxide in acute promyelocytic leukaemia predicts differentiation syndrome and treatment-related complications BRITISH JOURNAL OF HAEMATOLOGY 2024
Shedding light on resistance to asciminib BLOOD 2024
Real-Life Management of FLT3-Mutated AML: Single-Centre Experience over 24 Years CANCERS 2024
Clinical outcomes of ruxolitinib treatment in 595 intermediate-1 risk patients with myelofibrosis: The RUX-MF Real-World Study CANCER 2024
Equitable access to polycythemia vera treatments: addressing reimbursement disparities in Europe ANNALS OF HEMATOLOGY 2024
Epidemiology and disease characteristics of myelofibrosis: a comparative analysis between Italy and global perspectives FRONTIERS IN ONCOLOGY 2024
Is There a Better Therapeutic Time Window from Diagnosis to Treatment for Elderly Acute Myeloid Leukemia Patients Receiving Hypomethylating Agents? MEDITERRANEAN JOURNAL OF HEMATOLOGY AND INFECTIOUS DISEASES 2024
Treatment free remission (TFR) after second-generation tyrosine kinase inhibitors (2G-TKIs) treatment in chronic myeloid leukemia (CML): from feasibility to safety EXPERT OPINION ON DRUG SAFETY 2024
BCR::ABL1 digital PCR for treatment-free remission prediction in chronic myeloid leukemia patients: An individual participant data meta-analysis AMERICAN JOURNAL OF HEMATOLOGY 2024
Asciminib monotherapy in patients with chronic-phase chronic myeloid leukemia with the T315I mutation after ≥1 prior tyrosine kinase inhibitor: 2-year follow-up results LEUKEMIA 2024
Financial toxicity and health-related quality of life in long-term survivors of acute promyelocytic leukaemia BMJ SUPPORTIVE & PALLIATIVE CARE 2024
Are there new relevant therapeutic endpoints in the modern era of the BCR::ABL1 tyrosine kinase inhibitors in chronic myeloid leukemia? LEUKEMIA 2024
Pharmacotherapeutic advances for chronic myelogenous leukemia: beyond tyrosine kinase inhibitors EXPERT OPINION ON PHARMACOTHERAPY 2024
ROP-ET: a prospective phase III trial investigating the efficacy and safety of ropeginterferon alfa-2b in essential thrombocythemia patients with limited treatment options ANNALS OF HEMATOLOGY 2024

© Università degli Studi di Roma "La Sapienza" - Piazzale Aldo Moro 5, 00185 Roma